CompletedPHASE1, PHASE2NCT02841267
A Trial of PF-06252616 in Ambulatory Participants With LGMD2I
Studying FKRP-related limb-girdle muscular dystrophy R9
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kathryn Wagner
- Principal Investigator
- Kathryn R Wagner, MD/PhDHugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Intervention
- PF 06252616(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2016 – 2019
Study locations (1)
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Baltimore, Maryland, United States
Collaborators
Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02841267 on ClinicalTrials.govOther trials for FKRP-related limb-girdle muscular dystrophy R9
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05775848Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)ML Bio Solutions, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04800874Study of BBP-418 in Patients With LGMD2IML Bio Solutions, Inc.
See all trials for FKRP-related limb-girdle muscular dystrophy R9 →